Sartorius reported strong Q1 20 numbers (16.5% growth, 27% EBITDA margin), driven by Bioprocess solutions (BPS). Management now expects FY 20 topline growth of 15-19% (vs 10-13% earlier) with unchanged EBITDA margin expectations (27.5%). The COVID-19 impact has so far been neutral, with BPS benefiting from stocking tailwinds and LPS hurt by worsening macro conditions. In light of the ongoing uncertainties, the firm may reduce its FY19 dividend proposal. Factoring in the strong performance, we
22 Apr 2020
BPS lifts Q1 20 performance
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
BPS lifts Q1 20 performance
Sartorius AG (0NIQ:LON) | 13,825 0 0.0% | Mkt Cap: 10,352m
- Published:
22 Apr 2020 -
Author:
Virendra Chauhan -
Pages:
3
Sartorius reported strong Q1 20 numbers (16.5% growth, 27% EBITDA margin), driven by Bioprocess solutions (BPS). Management now expects FY 20 topline growth of 15-19% (vs 10-13% earlier) with unchanged EBITDA margin expectations (27.5%). The COVID-19 impact has so far been neutral, with BPS benefiting from stocking tailwinds and LPS hurt by worsening macro conditions. In light of the ongoing uncertainties, the firm may reduce its FY19 dividend proposal. Factoring in the strong performance, we